Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Novartis Ag ADR LICHTSTRASSE 35 BASEL V8 CH 4056 CHE

www.novartis.com Employees: 75,883 P: 41-61-324-1111 F: +41 613247826

Sector:

Medical

Description:

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.

Key Statistics

Overview:

Market Capitalization, $K 229,193,728
Enterprise Value, $K 247,332,736
Shares Outstanding, K 2,044,000
Annual Sales, $ 51,722 M
Annual Net Income, $ 11,941 M
Last Quarter Sales, $ 13,558 M
Last Quarter Net Income, $ 2,818 M
EBIT, $ 14,544 M
EBITDA, $ 20,658 M
60-Month Beta 0.53
% of Insider Shareholders 0.01%
% of Institutional Shareholders 13.12%
Float, K 2,043,796
% Float 99.99%
Short Volume Ratio 0.42

Growth:

1-Year Return 16.70%
3-Year Return 29.09%
5-Year Return 41.44%
5-Year Revenue Growth 6.26%
5-Year Earnings Growth 49.05%
5-Year Dividend Growth -81.91%

Per-Share Information:

Most Recent Earnings 1.98 on 01/31/25
Next Earnings Date 04/22/25
Earnings Per Share ttm 7.81
EPS Growth vs. Prev Qtr -3.88%
EPS Growth vs. Prev Year 29.41%
Annual Dividend Rate, $ 2.52
Annual Dividend Yield 2.24%
Most Recent Dividend 2.515 on 03/12/25
Next Ex-Dividends Date 03/12/25
Dividend Payable Date 03/11/14
Dividend Payout Ratio 31.53%
Most Recent Split 108-95 on 04/09/19

NVS Ratios

Ratio
Price/Earnings ttm 14.50
Price/Earnings forward 13.37
Price/Earnings to Growth 1.79
Return-on-Equity % 37.25%
Return-on-Assets % 15.85%
Profit Margin % 23.09%
Debt/Equity 0.67
Price/Sales 4.60
Price/Cash Flow 10.58
Price/Book 5.24
Book Value/Share 21.59
Interest Coverage 14.56

NVS Dividends

Date Value
03/12/25 $2.5150
03/07/24 $2.4310
10/04/23 $5.3440
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar